Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Christoph M. Hammers"'
Publikováno v:
The Journal of Dermatology. 48:317-323
The association of bullous pemphigoid (BP) with solid malignancies (SM) is a matter of controversy, as previous studies produced inconclusive findings. The aim of this study was to assess the risk of SM among patients with BP and to evaluate whether
Autor:
Arnon D. Cohen, Shira Zelber-Sagi, Christoph M. Hammers, Virginia A. Jones, Khalaf Kridin, Kyle T. Amber, Payal M. Patel, Giovanni Damiani
Publikováno v:
Immunologic Research
Data regarding the association between pemphigus and rheumatoid arthritis (RA) is inconclusive and yet to be firmly established. In the current study, we aimed to evaluate the risk of developing RA during the course of pemphigus. A large-scale popula
Autor:
Ralf Ludwig, Sabrina Patzelt, Christoph Hudemann, Rüdiger Eming, Christoph M. Hammers, Katja Bieber, Sören Dräger, Detlef Zillikens, Katharina Boch, Ewan A. Langan, Enno Schmidt
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 11, p e0259586 (2021)
PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE, Vol 16, Iss 11, p e0259586 (2021)
PLoS ONE, Vol 16, Iss 11 (2021)
Background Pemphigus vulgaris (PV) is a rare autoimmune blistering disease characterized by the development of autoantibodies targeting desmoglein (Dsg) 3, but also against Dsg1 in mucocutaneous disease. Given that existing PV animal models only reca
Autor:
Abed Abu-Elhija, Dana Tzur Bitan, Christoph M. Hammers, Enno Schmidt, Ralf Ludwig, Yochai Schonmann, Khalaf Kridin, Orly Weinstein, Erez Onn, Arnon D. Cohen
Publikováno v:
Dermatitis : contact, atopic, occupational, drug. 33(4)
BACKGROUND Although bullous pemphigoid (BP), atopic dermatitis (AD), and allergic rhinitis (AR) are associated with shared pathogenic mechanisms the epidemiological relationship between these conditions remains to be investigated. OBJECTIVE To evalua
Publikováno v:
Acta Dermato-Venereologica, Vol 101, Iss 9, p adv00535 (2021)
Drug survival reflects the real-life efficacy and safety of therapeutic agents. Evidence regarding the durability of adjuvant agents in the treatment of pemphigus is sparse. The aims of this study were to investigate the survival of adjuvant agents u
Autor:
Christoph M. Hammers, Sarah M. McDonald, Michael Jeffrey Cho, Gopal Sapparapu, Christoph T. Ellebrecht, James E. Crowe, Aimee S. Payne, Eric M. Mukherjee, Crystal E. Boudreaux
Publikováno v:
The Journal of Immunology. 197:1065-1073
Shared VH1-46 gene usage has been described in B cells reacting to desmoglein 3 (Dsg3) in the autoimmune disease pemphigus vulgaris (PV), as well as B cells responding to rotavirus capsid protein VP6. In both diseases, VH1-46 B cells bearing few to n
Autor:
Jennifer E. Hundt, D. Zillikens, Christoph M. Hammers, Ralf Ludwig, J. Johns, Christian Probst, L. Komorowski, Andreas Recke, Enno Schmidt, Takashi Hashimoto, Shirin Emtenani
Publikováno v:
Journal of Investigative Dermatology. 139:S221
Autor:
Jing Chen, Aimee S. Payne, Don L. Siegel, John R. Stanley, Christoph M. Hammers, Stephen Kacir, Chenyan Lin
Publikováno v:
Journal of Investigative Dermatology. 135:742-749
Pemphigus vulgaris (PV) is a prototypic tissue-specific autoantibody-mediated disease, in which anti-desmoglein 3 (Dsg3) IgG autoantibodies cause life-threatening blistering. We characterized the autoimmune B-cell response over 14 patient years in tw
Autor:
Ralf J. Ludwig, Karen Vanhoorelbeke, Frank Leypoldt, Ziya Kaya, Katja Bieber, Sandra M. McLachlan, Lars Komorowski, Jie Luo, Otavio Cabral-Marques, Christoph M. Hammers, Jon M. Lindstrom, Peter Lamprecht, Andrea Fischer, Gabriela Riemekasten, Claudia Tersteeg, Peter Sondermann, Basil Rapoport, Klaus-Peter Wandinger, Christian Probst, Asmaa El Beidaq, Enno Schmidt, Alan Verkman, Rudolf A. Manz, Falk Nimmerjahn
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Frontiers in Immunology
Frontiers in Immunology
Autoantibodies are frequently observed in healthy individuals. In a minority of these individuals, they lead to manifestation of autoimmune diseases, such as rheumatoid arthritis or Graves' disease. Overall, more than 2.5% of the population is affect
Autor:
Shirin Emtenani, J. Langenhan, Ralf Ludwig, Christoph M. Hammers, Detlef Zillikens, Jennifer E. Hundt, L. Komorowski, J. Johns, Enno Schmidt
Publikováno v:
Journal of Investigative Dermatology. 137:S256